Key result
Higher mitral TEER site volume is linked to ~6% lower 30-day mortality per ten annual cases.
Why the study?
Dissemination of novel procedures requires balancing access and quality; the temporal trends, geographic dispersion, and outcome associations of M-TEER site volume and regional density remained to be evaluated.
Does higher site volume or site density improve 30-day and 1-year mortality in patients undergoing M-TEER?
Observational (n=16,810)
Yes
Does higher site volume or site density improve 30-day and 1-year mortality in patients undergoing M-TEER?
Answers are grounded in this paper and cite their sources.
Higher institutional volume of M-TEER is associated with lower 30-day and 1-year mortality, emphasizing the need to balance geographic access with adequate site volume.
BACKGROUND: The dissemination of novel procedures should attempt to strike a balance between access and procedure quality. This study aimed to evaluate the temporal trends and geographic dispersion of mitral transcatheter edge-to-edge repair (M-TEER) sites and to examine the associations of site volume and site-to-population density with patient outcomes. METHODS: We used the Medicare administrative databases in the United States to identify sites performing M-TEER in patients aged 65 to 99 years from 2017 to 2020 and examined the annualized volume and site-to-population density (per million beneficiaries in each corresponding hospital referral region). A hierarchical Cox regression analysis accounting for site-level clustering was performed to assess the association of site volume and density with 30-day and 1-year all-cause mortality. RESULTS: We identified 456 sites performing M-TEER in 16 810 patients (median [interquartile range] age, 81 [75-86] years; female, 47%). The case number of M-TEER increased by 54% from 3125 in 2017 to 4820 in 2020, while sites performing M-TEER increased by 71% from 252 in 2017 to 432 in 2020, corresponding to a decline in the median patient-to-site distances from 37.1 kilometers (interquartile range, 14.4-105.0) to 28.6 kilometers (interquartile range, 12.8-74.9). Higher site volume (every 10 cases/y) was associated with lower 30-day (adjusted hazard ratio, 0.94 [95% CI, 0.91-0.99]) and 1 year (adjusted hazard ratio, 0.98 [95% CI, 0.96-1.00]) mortality, while there was insufficient evidence to determine the association between higher site density (every 1 site/million-beneficiaries) and 30-day (adjusted hazard ratio, 1.00 [95% CI, 0.99-1.02]) and 1-year (adjusted hazard ratio, 1.00 [95% CI, 0.99-1.01]) mortality. CONCLUSIONS: Although sites performing M-TEER have been rapidly expanding, we did not find associations between higher regional site density and patient mortality. Continuous careful planning in disseminating M-TEER while ensuring adequate procedure volume per site may optimize patient outcomes.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2025) conducted an observational in Mitral transcatheter edge-to-edge repair (M-TEER) (n=16,810). Higher site volume of M-TEER (every 10 cases/y) was evaluated on 30-day all-cause mortality (HR 0.94, 95% CI 0.91-0.99). Higher site volume of mitral transcatheter edge-to-edge repair (every 10 cases/y) was associated with lower 30-day mortality (adjusted HR 0.94; 95% CI 0.91-0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: